Health Condition 1: I348- Other nonrheumatic mitral valve disorders Health Condition 2: null- Patients requiring Warfarin Therapy
Conditions
Interventions
Intervention1: Warfarin: Warfarin dose based on genotype
Control Intervention1: Warfarin: Warfarin dose based on non genotype
Sponsors
King Edward Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients who are to be freshly started on warfarin treatment (naive) for atleast 3 months for various Cardiovascular indications. These are the following indications but not limited to a. Patient with valvular heart disease with atrial fibrillation/atrial flutter b.Nonvalvular atrial fibrillation with CHADVAS score >1 c.Patient with deep vein thrombosis, Pulmonary embolism requiring anticoagulation d. Dialated Cardiomyopathy with atrial fibrillation e. Hypertrophic Cardiomyopathy with atrial fibrillation f.Patients with documented thrombus in the left ventricular cavity g.Patients having chocked valve who have to undergo mechanical valve prosthesis 2.Aged 18 years and above of either gender 3.Patients willing to give voluntarily written informed consent 4.Patient willing to comply with protocol requirements
Exclusion criteria
Exclusion criteria: 1. Genotype (CYP2C9 and VKORC1) known to participant from prior testing or available in medical record 2.Pregnancy or lactation 3.Patients having history of renal and liver insufficiency 4.Any other clinical condition as per physicianâ??s judgment which compromises safety of the participant or credibility of the data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incremental cost effectiveness ratio of genotyping as compared to standard INR based dose adjustment.Timepoint: 90 days follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of mean time in therapeutic range (TIR) between two groups Timepoint: 90 days | — |
Countries
India
Contacts
Public ContactShital Bendkhale
King Edward Memorial Hospital
Outcome results
None listed